As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Cardiac safety evaluation is an important factor that must be checked before all kinds of new drugs enter clinical trials, and it is also the most important and serious degree in the early clinical research of innovative drugs. In recent years, some drugs that have been put into clinical application because Medicilon is a one-stop comprehensive outsourcing service for medical research and development, with an experienced team of experts, which can provide multi-level preclinical cardiac safety evaluation services from cells to whole animals.
Efficiently predict the reliability of drugs in early cardiac safety pharmacology, which is particularly important for reducing potential adverse reactions in clinical research. At present, China can provide a one-stop medical research and development that meets GLP standards and can be used for IND applications including cardiac safety evaluations There are not many service companies. Medicilon is one of them. The service details are as follows:
The non-target adverse reactions (ADR) of the alternative compound and the adverse reactions caused by the uneven reaction of the target will allow the compound to pass subsequent in vivo experiments to avoid potential adverse reactions.
◆Research on the mechanism of lead compounds;
◆Detect the influence of compounds on hERG ion channels, and provide comprehensive evaluation of its cardiac safety in various stages of drug screening and development;
◆ Detection at the cell level.
In vivo safety pharmacology research
◆The non-invasive telemetry system observes the ECG and hemodynamic changes of the whole animal, and can continuously monitor the effect of drugs on the cardiovascular system.
Patch clamp
DSI fully implantable non-invasive telemetry system
DSI fully implantable non-invasive telemetry system
◆High cost performance, short research period, fast project start;
◆The expert team has very rich project experience and can provide constructive solutions;
◆As a one-stop medical R&D outsourcing service company, early provision of cardiotoxicity evaluation information will help Medicilon to screen out alternative compounds with higher cardiac safety factors through a complete set of technical methods such as chemistry, efficacy, pharmacokinetics and preparations.